CinCor Pharma, Inc. Common Stock
CINC
CINC was delisted on the 23rd of February, 2023.
102 hedge funds and large institutions have $461M invested in CinCor Pharma, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 34 increasing their positions, 19 reducing their positions, and 19 closing their positions.
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
79% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 19
19% more funds holding
Funds holding: 86 → 102 (+16)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
62% less capital invested
Capital invested by funds: $1.21B → $461M (-$752M)
68% less call options, than puts
Call options by funds: $2.68M | Put options by funds: $8.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$37.9M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$17.1M |
| 3 |
BlackRock
New York
|
+$11.1M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$9.79M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$9.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$43.1M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
-$35.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$24.7M |
| 4 |
PA
Perceptive Advisors
New York
|
-$17.4M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$6.42M |
CINC Hedge Fund Activity: Q4 2022 in Review
102 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q4 2022, worth a combined $461M — down 62% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CINC positions and 19 closed out — a net gain of 16 holders — while 34 added to existing stakes and 19 trimmed.
The largest buyer was OrbiMed, adding an estimated $37.9M. The largest seller was BVF Inc, exiting entirely with an estimated $43.1M sold.
- 102 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q4 2022, up from 86 in Q3 2022.
- Funds reported $461M of CinCor Pharma, Inc. Common Stock stock for Q4 2022, down 62% quarter-over-quarter.
- 35 funds opened new CinCor Pharma, Inc. Common Stock positions in Q4 2022 and 19 closed out, a net change of +16 holders.
- The largest CinCor Pharma, Inc. Common Stock buyer in Q4 2022 was OrbiMed, an estimated $37.9M added.
- The largest CinCor Pharma, Inc. Common Stock seller in Q4 2022 was BVF Inc, an estimated $43.1M sold.
Based on aggregated 13F filings for Q4 2022.